Valuation: Outlook Therapeutics, Inc.

Market Cap 101M 91.11M 84.27M 76.04M 143M 9.48B 148M 1.01B 401M 5.06B 377M 369M 16.07B P/E 2026 *
-0.71x
P/E 2027 * -1.91x
Enterprise Value 101M 91.11M 84.27M 76.04M 143M 9.48B 148M 1.01B 401M 5.06B 377M 369M 16.07B EV / Sales 2026 *
147x
EV / Sales 2027 * 2.28x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day-6.16%
1 week-5.36%
Current month-11.77%
1 month-17.40%
3 months-45.40%
6 months+81.06%
Current year-73.86%
1 week 0.41
Extreme 0.41015
0.5
1 month 0.41
Extreme 0.4086
0.6
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
12.85
5 years 0.16
Extreme 0.1611
42.4
10 years 0.16
Extreme 0.1611
635.2
Manager TitleAgeSince
Chief Executive Officer 54 2025-06-30
Director of Finance/CFO 58 2026-08-31
Chief Tech/Sci/R&D Officer - 2023-01-18
Director TitleAgeSince
Director/Board Member 65 2015-12-10
Chairman 41 2025-01-30
Director/Board Member 50 2017-10-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Chief Financial Officer

500,000 0.3122%
8/14/26 Buy

Chief Executive Officer

202,020 0.0832%
8/14/26 Buy

Chief Executive Officer

303,030 0.1249%
Change 5-day change 1-year change 3-year change Capi.($)
-6.16%-5.36%-73.69%-95.37% 101M
-2.69%-0.48%+53.97%+66.82% 66.33B
+0.02%+2.90%+10.88%+95.24% 60.62B
+0.68%+1.61%+24.21%+89.64% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
+2.31%-4.18%+77.58%+59.74% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average -0.54%-0.49%+25.86%+149.95% 41B
Weighted average by Cap. -0.23%+0.20%+36.68%+152.78%

Financials

2026 *2027 *
Net sales 683K 619K 572K 516K 973K 64.37M 1.01M 6.87M 2.73M 34.38M 2.56M 2.51M 109M 44.07M 39.94M 36.94M 33.33M 62.81M 4.16B 65.02M 444M 176M 2.22B 165M 162M 7.05B
Net income -65.1M -58.99M -54.57M -49.23M -92.78M -6.14B -96.05M -655M -260M -3.28B -244M -239M -10.41B -44.43M -40.27M -37.24M -33.6M -63.33M -4.19B -65.56M -447M -177M -2.24B -167M -163M -7.1B
Net Debt - -
Projected Income Statement - Annual - Outlook Therapeutics, Inc.
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
26-11-13 $0.4130 -6.16% 3,025,431
26-11-12 $0.4401 -8.50% 2,444,691
26-11-11 $0.4810 +4.43% 2,343,048
26-11-10 $0.4606 +0.28% 1,064,528
26-11-09 $0.4593 +5.25% 1,963,231
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Outlook Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.4130USD
Average target price
5.025USD
Spread / Average Target
+1,116.71%
  1. Stock Market
  2. Stocks
  3. OTLK Stock